Skip to content

Study · Randomized controlled trial · n = 9 · 1997

4 results

Different effects of growth hormone releasing peptide (GHRP-6) and GH-releasing hormone on GH release in endogenous and exogenous hypercortisolism.

Borges MH, DiNinno FB, Lengyel AM

Clinical endocrinology1 Jun 1997Cited by 11 (Europe PMC)

PMID9274702 (opens in a new tab)DOI10.1046/j.1365-2265.1997.1981008.x (opens in a new tab)PepBankPUB-09274702
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with exogenous glucocorticoid excess, the GH response to GHRP‑6 alone did not differ from controls.

    In plain wordsIn people taking glucocorticoid drugs, GHRP‑6 raised growth hormone to a similar level as in controls.

    Peptide
    GHRP-6
    Outcome
    No significant changePeak GH after GHRP-6 in exogenous glucocorticoid excess versus controls
    Study

    n = 9

    Comparator
    Controls
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    1 microgram/kg · intravenousAs given in this study (human).

    Source sentences

    Summary
    There were no differences in the GH responses to GHRP-6 alone or in combination with GHRH when controls were compared to the exogenous group.
    1 context sentence
    Summary · context
    Six patients with endogenous hypercortisolism, nine with exogenous glucocorticoid excess and 10 normal controls were submitted to three tests, in random order, with GHRH (100 micrograms), GHRP-6 (1 microgram/ kg) or GHRP+GHRP-6, in the same doses, i.v., on separate days.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients with endogenous hypercortisolism, the peak GH after GHRP‑6 alone was lower than in controls and in exogenous hypercortisolism.

    In plain wordsIn people with natural cortisol excess, GHRP‑6 raised growth hormone less than in controls and in people on glucocorticoid drugs.

    Peptide
    GHRP-6
    Outcome
    DecreasePeak GH after GHRP-6 in endogenous hypercortisolism
    Study

    n = 6

    Comparator
    Controls and exogenous glucocorticoid excess
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    1 microgram/kg · intravenousAs given in this study (human).

    Source sentences

    Summary
    The endogenous group had lower peak GH values after GHRP-6 alone (7.7 +/- 1.9) or together with GHRH (18.8 +/- 5.8) than those observed in controls (GHRP-6: 22.1 +/- 3.6; GHRH+GHRP-6: 77.4 +/- 15.0) and in exogenous hypercortisolism (27.4 +/- 6.2 and 78.1 +/- 19.9).
    1 context sentence
    Summary · context
    Six patients with endogenous hypercortisolism, nine with exogenous glucocorticoid excess and 10 normal controls were submitted to three tests, in random order, with GHRH (100 micrograms), GHRP-6 (1 microgram/ kg) or GHRP+GHRP-6, in the same doses, i.v., on separate days.

Studies that did not test the peptide alone2

In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking GHRP-6.

  1. 03HumanNot a test of GHRP-6 aloneRandomized controlled trialEfficacy outcome

    In patients with exogenous glucocorticoid excess, the GH response to GHRP‑6 in combination with GHRH did not differ from controls.

    In plain wordsIn people taking glucocorticoid drugs, GHRP‑6 with GHRH raised growth hormone to a similar level as in controls.

    Peptide
    GHRP-6
    Outcome
    No significant changeGH response to GHRH plus GHRP-6 in exogenous glucocorticoid excess versus controls
    Study

    n = 9

    Comparator
    Controls
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    There were no differences in the GH responses to GHRP-6 alone or in combination with GHRH when controls were compared to the exogenous group.
    1 context sentence
    Summary · context
    Six patients with endogenous hypercortisolism, nine with exogenous glucocorticoid excess and 10 normal controls were submitted to three tests, in random order, with GHRH (100 micrograms), GHRP-6 (1 microgram/ kg) or GHRP+GHRP-6, in the same doses, i.v., on separate days.

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

  2. 04HumanNot a test of GHRP-6 aloneRandomized controlled trialEfficacy outcome

    In patients with endogenous hypercortisolism, the peak GH after GHRH plus GHRP‑6 was lower than in controls and in exogenous hypercortisolism.

    In plain wordsIn people with natural cortisol excess, GHRP‑6 with GHRH raised growth hormone less than in controls and in people on glucocorticoid drugs.

    Peptide
    GHRP-6
    Outcome
    DecreasePeak GH after GHRH plus GHRP-6 in endogenous hypercortisolism
    Study

    n = 6

    Comparator
    Controls and exogenous glucocorticoid excess
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    The endogenous group had lower peak GH values after GHRP-6 alone (7.7 +/- 1.9) or together with GHRH (18.8 +/- 5.8) than those observed in controls (GHRP-6: 22.1 +/- 3.6; GHRH+GHRP-6: 77.4 +/- 15.0) and in exogenous hypercortisolism (27.4 +/- 6.2 and 78.1 +/- 19.9).
    1 context sentence
    Summary · context
    Six patients with endogenous hypercortisolism, nine with exogenous glucocorticoid excess and 10 normal controls were submitted to three tests, in random order, with GHRH (100 micrograms), GHRP-6 (1 microgram/ kg) or GHRP+GHRP-6, in the same doses, i.v., on separate days.

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.